Who is sponsoring NCT04923386?

NCT04923386 is sponsored by Levenson, David I., M.D..

What drugs are being tested in NCT04923386?

Interventions in NCT04923386: None (not interventional).

What condition does NCT04923386 study?

NCT04923386 studies Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Hyperglycemia, Vaccine Adverse Reaction.

Is NCT04923386 still recruiting?

NCT04923386 is currently completed. Last updated 17 August 2022.

Last reviewed 2022-08-17 · How we verify

NCT04923386

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

mRNA Based-Covid-19 Vaccine Effects on Blood Glucose Levels

Completed Last updated 17 August 2022

What this trial tests

trial testing None (not interventional) in Diabetes Mellitus, Type 2 in 25 participants. Completed in 1 February 2022.

Timeline

15 June 2021

Primary endpoint
15 December 2021

1 February 2022

Quick facts

Lead sponsor	Levenson, David I., M.D.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	25
Start date	15 June 2021
Primary completion	15 December 2021
Estimated completion	1 February 2022
Sites	1 location across United States

Drugs / interventions tested

None (not interventional)

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →
Hyperglycemia — all drugs for Hyperglycemia →
Vaccine Adverse Reaction — all drugs for Vaccine Adverse Reaction →

Sponsor

Levenson, David I., M.D.

Who can join

18 and older, any sex, with Diabetes Mellitus, Type 2 or Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine if patients with a history of Diabetes Mellitus Type I or II developed a change in blood glucose levels as reported on Continuous glucose monitoring devices (CGMS) within the first week following administration of each dose of the COVID-19 vaccine.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

COVID-19 Vaccines and Hyperglycemia-Is There a Need for Postvaccination Surveillance?
Samuel SM, Varghese E, Triggle CR, Büsselberg D. · · 2022 · cited 20× · PMID 35335086 · DOI 10.3390/vaccines10030454
European Safety Analysis of mRNA and Viral Vector COVID-19 Vaccines on Glucose Metabolism Events.
di Mauro G, Mascolo A, Longo M, Maiorino MI, et al · · 2022 · cited 11× · PMID 35745596 · DOI 10.3390/ph15060677
Transient Hyperglycemia in a Patient With Type 2 Diabetes After COVID-19 Messenger RNA Vaccination: A Case Report.
Okon-Umoren A, Yaphe S, Smith A, Passalacqua KD, et al · · 2024 · PMID 39105031 · DOI 10.7759/cureus.63983

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Levenson, David I., M.D. trials

Trials by the same sponsor.

NCT02779816 — Adaptive Device for Insulin Pens for Arthritic Patients · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04923386 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Levenson, David I., M.D.
Last refreshed: 17 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04923386.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing